{"analyses":[{"ciLowerLimit":"0.37","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.90","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0133","paramType":"Hazard Ratio (HR)","paramValue":"0.58","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.44","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6815","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to low number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to low number of events.","groupId":"OG001","lowerLimit":"36.9","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to low number of events.","groupId":"OG002","lowerLimit":"22.1","upperLimit":"NA","value":"37.2"},{"comment":"Not estimable due to low number of events.","groupId":"OG003","lowerLimit":"24.5","upperLimit":"NA","value":"30.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"93"},{"groupId":"OG003","value":"91"}],"units":"Participants"}],"description":"DMFS was defined as the time from randomization until the date of diagnosis of distant (i.e. non-locoregional) metastases or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"OG000","title":"Cohort 1 Vemurafenib"},{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"OG001","title":"Cohort 1 Placebo"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"OG002","title":"Cohort 2 Vemurafenib"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"OG003","title":"Cohort 2 Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants enrolled in the study, whether or not they had received study medication.","reportingStatus":"POSTED","timeFrame":"From randomization until the date of diagnosis of distant (i.e., non-locoregional) metastases or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years)","title":"Distant Metastasis-Free Survival (DMFS) as Assessed Using Contrast-Enhanced MRI or Contrast Enhanced CT","type":"SECONDARY","unitOfMeasure":"months"}